Juvenile Idiopathic Arthritis (JIA)
Conditions
Keywords
Arthritis, Juvenile, tofacitinib [Supplementary Concept], Janus Kinase Inhibitors
Brief summary
This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.
Interventions
DRUGTofacitinib
Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).
Sponsors
Consorci Sanitari de l'Alt Penedès i Garraf
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist. Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA. Age under 18 years at the time of the treatment indication with tofacitinib.
Exclusion criteria
Participants diagnosed with any of the following conditions: Reactive arthritis Arthritis associated with inflammatory bowel disease Arthritis associated with another autoimmune disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| JADAS-10 | Baseline and 12 months | Change in the Juvenile Arthritis Disease Activity Score (JADAS-10) score at 12 months of treatment with tofacitinib. Range score: 0 to 10, the less score the better |
Countries
Spain
Contacts
Primary ContactNoemí Casaponsa
Outcome results
None listed